IP Library Granted Patent US 7,452,987
Granted Patent B2
US 7,452,987 · App. 10/633,630 · Granted Nov 18, 2008

Interfering RNA molecules

Assignee: Silence Therapeutics Aktiengesellschaft (AG)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,452,987
App. No.
10/633,630
Granted
Nov 18, 2008
Kind
B2
Abstract

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.

Claims (15)

1. A nucleic acid molecule comprising a first strand and a second strand,

wherein said first strand comprises a first stretch that is complementary to a target nucleic acid,

wherein said second strand comprises a second stretch that is the same length as said first stretch and that is complementary to said first stretch,

wherein said first strand and said second strand form a double-stranded structure consisting of said first stretch and said second stretch,

wherein said first stretch and said second stretch each consist of contiguous alternating single 2′-O-methyl modified and single unmodified ribonucleotides,

wherein said 2′-O-methyl modified and unmodified ribonucleotides in each stretch are linked by phosphodiester bonds,

wherein each modified ribonucleotide in said first stretch is base paired with a said unmodified ribonucleotide in said second stretch,

wherein each modified ribonucleotide in said second stretch is base paired with a said unmodified ribonucleotide in said first stretch, and

wherein each stretch consists of 15-23 ribonucleotides.

2. The nucleic acid molecule according to claim 1 , wherein said first strand and said second strand are each 15-23 nucleotides long.

3. The nucleic acid molecule according to claim 1 , wherein said first strand and said second strand are each 17-23 nucleotides long.

4. The nucleic acid molecule according to claim 1 , wherein said first strand and said second strand are each 19 nucleotides long.

5. The nucleic acid molecule according to claim 1 , wherein said first strand and said second strand are each 21 nucleotides long.

6. The nucleic acid molecule according to claim 1 , wherein said first strand and said second strand are each 23 nucleotides long.

7. The nucleic acid molecule according to claim 1 , wherein said nucleic acid is blunt ended at both ends.

Assignments (3)
CHANGE OF NAME Recorded Jan 15, 2015
From: SILENCE THERAPEUTICS AG
To: SILENCE THERAPEUTICS GMBH
Reel/Frame 034767/0324 →
CHANGE OF NAME Recorded Mar 26, 2008
From: ATUGEN AG (AKTIENGESELLSCHAFT)
To: SILENCE THERAPEUTICS AKTIENGESELLSCHAFT (AG)
Reel/Frame 020700/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2004
From: GIESE, KLAUS; KAUFMANN, JOERG; KLIPPEL-GIESE, ANKE
To: ATUGEN AG
Reel/Frame 014958/0009 →
Priority Claims (2)
EP 02017601 · Aug 5, 2002 · regional
EP 03008383 · Apr 10, 2003 · regional
Continuity (2)
Provisional Application 6040254100 · Aug 12, 2002
Related Publication 20040180351A1 · Sep 16, 2004